TY - JOUR
T1 - Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study
AU - Hare, Joshua M.
AU - Mangal, Brian
AU - Brown, Joanne
AU - Fisher, Charles
AU - Freudenberger, Ronald
AU - Colucci, Wilson S.
AU - Mann, Douglas L.
AU - Liu, Peter
AU - Givertz, Michael M.
AU - Schwarz, Richard P.
PY - 2008/6/17
Y1 - 2008/6/17
N2 - Objectives: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy. Background: Increased XO activity may contribute to heart failure pathophysiology. Methods: Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life. Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by ∼2 mg/dl (p <0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA
AB - Objectives: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy. Background: Increased XO activity may contribute to heart failure pathophysiology. Methods: Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life. Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by ∼2 mg/dl (p <0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA
UR - http://www.scopus.com/inward/record.url?scp=44649122196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44649122196&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2008.01.068
DO - 10.1016/j.jacc.2008.01.068
M3 - Article
C2 - 18549913
AN - SCOPUS:44649122196
SN - 0735-1097
VL - 51
SP - 2301
EP - 2309
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 24
ER -